SITC Summit on Immunomodulation of Antibody-drug Conjugates

The Society for Immunotherapy of Cancer (SITC) will host the Summit on Immunomodulation of Antibody-drug Conjugates on Wednesday, June 26, 2024 from 11 a.m.–3:30 p.m. EDT. The virtual summit is a free, public event that features invited speakers, expert panel discussions, and attendee question and answer periods. The multi-stakeholder virtual summit will feature over 25 panelists representing academic research and industry around the world.

PROGRAM SUMMARY
The SITC Summit on Immunomodulation of Antibody-drug Conjugates will highlight the latest translational and clinical research on antibody-drug conjugates (ADCs) and their impacts on the immune system, anti-tumor immunity, and the tumor microenvironment. Topics to be addressed at the summit include impact of ADCs on the immune system, clinical considerations surrounding ADCs, ADC combination therapies, and next-generation immunoconjugates.
This open-door virtual educational event will present the current state and future directions of the field and feature participation of invited stakeholders involved in ADC research and development, including clinicians and researchers from academia and industry.

PROGRAM ORGANIZERS

Timothy B. Lowinger, PhD
Mersana Therapeutics

Sara Tolaney, MD, MPH
Dana-Farber Cancer Institute

Alfred Zippelius, MD
University Hospital Basel

Register: sitcancer.org/immunomodulation-vs

SUMMIT GOALS & OBJECTIVES
- Elucidate the mechanistic aspects of ADC monotherapies and combination therapies
- Explore the effects of ADCs on the immune system, tumor microenvironment, and anti-tumor immunity
- Review clinical considerations for ADC-based therapies
- Discuss the rationale of using immunoconjugates for targeted cancer therapy